S&P 500   4,277.67 (-0.25%)
DOW   33,371.75 (-0.18%)
QQQ   359.49 (-0.49%)
AAPL   173.21 (-0.31%)
MSFT   319.93 (-0.58%)
META   304.82 (-0.65%)
GOOGL   133.33 (-0.63%)
AMZN   127.14 (-1.79%)
TSLA   247.61 (-1.59%)
NVDA   447.39 (-0.10%)
NIO   8.56 (-2.62%)
BABA   84.41 (-2.45%)
AMD   102.10 (-1.13%)
T   14.71 (+0.27%)
F   12.14 (-1.38%)
MU   68.63 (+0.99%)
CGC   0.72 (-2.97%)
GE   109.62 (+0.76%)
DIS   80.97 (-0.86%)
AMC   8.06 (-1.10%)
PFE   33.92 (-0.06%)
PYPL   58.20 (-0.61%)
NFLX   377.02 (-0.87%)
S&P 500   4,277.67 (-0.25%)
DOW   33,371.75 (-0.18%)
QQQ   359.49 (-0.49%)
AAPL   173.21 (-0.31%)
MSFT   319.93 (-0.58%)
META   304.82 (-0.65%)
GOOGL   133.33 (-0.63%)
AMZN   127.14 (-1.79%)
TSLA   247.61 (-1.59%)
NVDA   447.39 (-0.10%)
NIO   8.56 (-2.62%)
BABA   84.41 (-2.45%)
AMD   102.10 (-1.13%)
T   14.71 (+0.27%)
F   12.14 (-1.38%)
MU   68.63 (+0.99%)
CGC   0.72 (-2.97%)
GE   109.62 (+0.76%)
DIS   80.97 (-0.86%)
AMC   8.06 (-1.10%)
PFE   33.92 (-0.06%)
PYPL   58.20 (-0.61%)
NFLX   377.02 (-0.87%)
S&P 500   4,277.67 (-0.25%)
DOW   33,371.75 (-0.18%)
QQQ   359.49 (-0.49%)
AAPL   173.21 (-0.31%)
MSFT   319.93 (-0.58%)
META   304.82 (-0.65%)
GOOGL   133.33 (-0.63%)
AMZN   127.14 (-1.79%)
TSLA   247.61 (-1.59%)
NVDA   447.39 (-0.10%)
NIO   8.56 (-2.62%)
BABA   84.41 (-2.45%)
AMD   102.10 (-1.13%)
T   14.71 (+0.27%)
F   12.14 (-1.38%)
MU   68.63 (+0.99%)
CGC   0.72 (-2.97%)
GE   109.62 (+0.76%)
DIS   80.97 (-0.86%)
AMC   8.06 (-1.10%)
PFE   33.92 (-0.06%)
PYPL   58.20 (-0.61%)
NFLX   377.02 (-0.87%)
S&P 500   4,277.67 (-0.25%)
DOW   33,371.75 (-0.18%)
QQQ   359.49 (-0.49%)
AAPL   173.21 (-0.31%)
MSFT   319.93 (-0.58%)
META   304.82 (-0.65%)
GOOGL   133.33 (-0.63%)
AMZN   127.14 (-1.79%)
TSLA   247.61 (-1.59%)
NVDA   447.39 (-0.10%)
NIO   8.56 (-2.62%)
BABA   84.41 (-2.45%)
AMD   102.10 (-1.13%)
T   14.71 (+0.27%)
F   12.14 (-1.38%)
MU   68.63 (+0.99%)
CGC   0.72 (-2.97%)
GE   109.62 (+0.76%)
DIS   80.97 (-0.86%)
AMC   8.06 (-1.10%)
PFE   33.92 (-0.06%)
PYPL   58.20 (-0.61%)
NFLX   377.02 (-0.87%)
Positive News SentimentPositive News
NYSE:ZYME

Zymeworks (ZYME) Stock Forecast, Price & News

$6.14
-0.05 (-0.81%)
(As of 09:45 AM ET)
Compare
Today's Range
$6.12
▼
$6.21
50-Day Range
$6.19
▼
$7.97
52-Week Range
$4.86
▼
$10.80
Volume
11,890 shs
Average Volume
605,910 shs
Market Capitalization
$416.48 million
P/E Ratio
2.19
Dividend Yield
N/A
Price Target
$12.44
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media

Zymeworks MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
101.0% Upside
$12.44 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.25) to ($1.67) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.46 out of 5 stars

Medical Sector

204th out of 975 stocks

Pharmaceutical Preparations Industry

71st out of 455 stocks

See Top Rated MarketRank™ Stocks Here

ZYME stock logo

About Zymeworks (NYSE:ZYME) Stock

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include Zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, colorectal, and endometrial cancers; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. The company has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.

ZYME Price History

ZYME Stock News Headlines

September 23, 2023 | americanbankingnews.com
Zymeworks Inc. (NYSE:ZYME) Receives Average Rating of "Moderate Buy" from Brokerages
September 22, 2023 | benzinga.com
Revolutionary Cancer Treatment Advances Promise Brighter Future Amid Federal Funding Uncertainty
October 3, 2023 | Wall Street Fundamentals (Ad)
The "Plug and Play" Model Putting Online Giants to Shame
While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."
September 11, 2023 | msn.com
Adding Zymeworks To My Value Watchlist (Initial Buy Rating)
August 15, 2023 | msn.com
HC Wainwright & Co. Reiterates Zymeworks BC (ZYME) Neutral Recommendation
August 15, 2023 | markets.businessinsider.com
H.C. Wainwright Sticks to Its Hold Rating for Zymeworks (ZYME)
August 11, 2023 | msn.com
Zymeworks GAAP EPS of -$0.76 misses by $0.27, revenue of $7M misses by $9.97M
August 10, 2023 | seekingalpha.com
Zymeworks Inc. 2023 Q2 - Results - Earnings Call Presentation
October 3, 2023 | Edge On The Street (Ad)
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
August 10, 2023 | markets.businessinsider.com
Zymeworks earnings: here's what Wall Street expects
July 22, 2023 | fool.com
Zymeworks (NYSE: ZYME)
July 19, 2023 | finance.yahoo.com
Zymeworks To Host Second Quarter 2023 Results Conference Call
June 30, 2023 | finanznachrichten.de
Zymeworks Inc.: Zymeworks Appoints New Director
June 29, 2023 | finance.yahoo.com
Zymeworks Appoints New Director
June 28, 2023 | seekingalpha.com
Zymeworks joins Russell 3000, Russell 2000, and Russell microcap indexes
June 26, 2023 | finanznachrichten.de
Zymeworks Inc.: Zymeworks Set to Join Russell 3000, Russell 2000, and Russell Microcap Indexes
June 26, 2023 | finance.yahoo.com
Zymeworks Set to Join Russell 3000®, Russell 2000®, and Russell Microcap® Indexes
June 22, 2023 | benzinga.com
Over $27M Bet On Zymeworks? Check Out These 3 Stocks Insiders Are Buying
June 20, 2023 | seekingalpha.com
Zymeworks: Marking Time
June 7, 2023 | msn.com
HC Wainwright & Co. Reiterates Zymeworks BC (ZYME) Prior Recommendation
June 6, 2023 | markets.businessinsider.com
7 Analysts Have This to Say About Zymeworks
June 6, 2023 | markets.businessinsider.com
Zymeworks (ZYME) Receives a Hold from H.C. Wainwright
May 29, 2023 | markets.businessinsider.com
Stifel Nicolaus Remains a Buy on Zymeworks (ZYME)
May 25, 2023 | markets.businessinsider.com
Zymeworks (ZYME) Gets a Buy from Stifel Nicolaus
May 18, 2023 | msn.com
Citigroup Maintains Zymeworks BC (ZYME) Buy Recommendation
May 18, 2023 | marketwatch.com
Zymeworks President, Chief Operating Officer Neil Klompas to Leave >ZYME
May 18, 2023 | markets.businessinsider.com
What 6 Analyst Ratings Have To Say About Zymeworks
See More Headlines
Receive ZYME Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zymeworks and its competitors with MarketBeat's FREE daily newsletter.

ZYME Company Calendar

Last Earnings
8/10/2023
Today
10/03/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSE:ZYME
Previous Symbol
NASDAQ:ZYME
CUSIP
N/A
CIK
1403752
Web
www.zymeworks.com
Phone
(302) 274-8744
Fax
604-737-7077
Employees
237
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$12.44
High Stock Price Forecast
$19.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+101.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
8 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$2.80
Trailing P/E Ratio
2.21
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$124.34 million
Net Margins
41.56%
Pretax Margin
44.69%
Return on Equity
46.66%
Return on Assets
34.59%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.49
Quick Ratio
4.49

Sales & Book Value

Annual Sales
$412.48 million
Price / Sales
1.02
Cash Flow
$2.11 per share
Price / Cash Flow
2.93
Book Value
$7.82 per share
Price / Book
0.79

Miscellaneous

Outstanding Shares
67,830,000
Free Float
66,721,000
Market Cap
$419.87 million
Optionable
Optionable
Beta
0.96
Beginner's Guide to Pot Stock Investing Cover
Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Mr. Kenneth H. Galbraith C.A. (Age 60)
    CEO & Chairman
    Comp: $1.22M
  • Dr. Christopher Astle Ph.D. (Age 43)
    Sr. VP & CFO
    Comp: $721.23k
  • Ms. Bijal Desai M.B.A.
    Exec. Director of Corp. Fin., FP&A & Procurement
  • Mr. Mark Hollywood (Age 53)
    Exec. VP and Head of Technical & Manufacturing Operations
  • Dr. Paul Moore Ph.D. (Age 56)
    Chief Scientific Officer
  • Jack W. Spinks
    Associate Director of Investor Relations
  • Mr. Daniel Dex J.D.
    Ph.D., Sr. VP, Corp. Sec. & Gen. Counsel
  • Diana Papove
    Sr. Mang. of Corp. Communications
  • Ms. Laura O'Connor
    Exec. Director & Head of Global HR
  • Dr. Jeffrey Smith M.D.
    Sr. VP of Early-Stage Devel.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













ZYME Stock - Frequently Asked Questions

Should I buy or sell Zymeworks stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Zymeworks in the last twelve months. There are currently 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ZYME shares.
View ZYME analyst ratings or view top-rated stocks.

What is Zymeworks' stock price forecast for 2023?

8 brokerages have issued 1-year price objectives for Zymeworks' stock. Their ZYME share price forecasts range from $8.00 to $19.00. On average, they expect the company's stock price to reach $12.44 in the next year. This suggests a possible upside of 101.0% from the stock's current price.
View analysts price targets for ZYME or view top-rated stocks among Wall Street analysts.

How have ZYME shares performed in 2023?

Zymeworks' stock was trading at $7.86 at the beginning of 2023. Since then, ZYME stock has decreased by 21.2% and is now trading at $6.19.
View the best growth stocks for 2023 here.

When is Zymeworks' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our ZYME earnings forecast.

How were Zymeworks' earnings last quarter?

Zymeworks Inc. (NYSE:ZYME) announced its quarterly earnings data on Thursday, August, 10th. The company reported ($0.76) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by $0.25. The company earned $7 million during the quarter, compared to analysts' expectations of $12.86 million. Zymeworks had a net margin of 41.56% and a trailing twelve-month return on equity of 46.66%.

What ETF holds Zymeworks' stock ?

Invesco Russell 2000 Dynamic Multifactor ETF holds 148,747 shares of ZYME stock, representing 0.32% of its portfolio.

What is Ali Tehrani's approval rating as Zymeworks' CEO?

9 employees have rated Zymeworks Chief Executive Officer Ali Tehrani on Glassdoor.com. Ali Tehrani has an approval rating of 100% among the company's employees. This puts Ali Tehrani in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 86.0% of employees surveyed would recommend working at Zymeworks to a friend.

What other stocks do shareholders of Zymeworks own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zymeworks investors own include Advanced Micro Devices (AMD), Gilead Sciences (GILD), Just Energy Group (JE), NVIDIA (NVDA), Just Energy Group (JE), PayPal (PYPL), Alibaba Group (BABA), Cronos Group (CRON), CRISPR Therapeutics (CRSP) and Tesla (TSLA).

When did Zymeworks IPO?

(ZYME) raised $65 million in an initial public offering on Friday, April 28th 2017. The company issued 4,500,000 shares at a price of $13.00-$16.00 per share. Citigroup, Barclays, Wells Fargo Securities and Canaccord Genuity acted as the underwriters for the IPO and Cormark Securities was co-manager.

What is Zymeworks' stock symbol?

Zymeworks trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZYME."

How do I buy shares of Zymeworks?

Shares of ZYME stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Zymeworks' stock price today?

One share of ZYME stock can currently be purchased for approximately $6.19.

How much money does Zymeworks make?

Zymeworks (NYSE:ZYME) has a market capitalization of $419.87 million and generates $412.48 million in revenue each year. The company earns $124.34 million in net income (profit) each year or $2.80 on an earnings per share basis.

How many employees does Zymeworks have?

The company employs 237 workers across the globe.

How can I contact Zymeworks?

Zymeworks' mailing address is 1385 WEST 8TH AVENUE SUITE 540, VANCOUVER A1, V6H 3V9. The official website for the company is www.zymeworks.com. The company can be reached via phone at (302) 274-8744, via email at ir@zymeworks.com, or via fax at 604-737-7077.

This page (NYSE:ZYME) was last updated on 10/3/2023 by MarketBeat.com Staff

My Account -